PD-1

[Advanced Healthcare Materials] The construction of a 1,3-propanesultone-grafted zwitterionic dendrimer-entrapped gold nanoparticle platform chelated with Gd(III) for immune checkpoint modulation is reported.

[Trends in Molecular Medicine] Researchers examined the recently discovered pathways involved in PD-L1 expression and highlight the relevant druggable strategies that are being developed to both improve the response rate and avoid the onset of resistance.

[Nature Immunology] Scientists found that tumor-infiltrating follicular regulatory T cells were prevalent in tumor tissues of several cancer types.

[Nature Medicine] Investigators studied a patient with inherited PD-1 deficiency and tuberculosis who died of pulmonary autoimmunity. The patient’s leukocytes did not express PD-1 or respond to PD-1-mediated suppression.

[Proceedings of the National Academy of Sciences of the United States of America] A protease-activated prodrug form of the anti-mouse CD137 agonist antibody 1D8 was constructed and found to be selectively activated in the tumor microenvironment.

[Oncogene] Despite its well-documented inhibitory effects, higher PD-1 expression in tumor-infiltrating lymphocytes was significantly associated with longer survival in triple-negative breast cancer patients.